urelumab   Click here for help

GtoPdb Ligand ID: 9311

Synonyms: BMS 663513 | BMS-663513
Immunopharmacology Ligand
Compound class: Antibody
Comment: Urelumab (BMS-663513) a fully human lgG4 monoclonal antibody with agonist activity at the tumour necrosis factor (TNF) receptor, 4-1BB (TNFRSF9). It is being investigated for potential clinical immunostimulatory activity in the immuno-oncology setting [2-4].
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Peptide sequences for urelumab are identical matches for peptides claimed in patent WO2005035584, which leads to identification of clone 20H4-9-IgG4 [1].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Urelumab (BMS-663513) is being evaluated in Phase 2 clinical trials for efficacy against solid (e.g. melanoma, urothelial carcinoma, bladder cancer) and liquid (e.g. leukemia, B-cell non-Hodgkins lymphoma) tumours. Click here to link to ClinicalTrials.gov's list of Phase 2 urelumab trials.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Urelumab acts as a ligand, activating 4-1BB and leading to enhanced T cell activity and cytokine production, which elicits improved destruction of cancer cells. It is hypothesised that combining this immune system activation with checkpoint inhibition (e.g. with anti-PD-1, or anti CTLA-4 antibodies) will offer more effective therapy against many types of cancer [4].